About Cellerant
Cellerant is a Healthcare company based in San Carlos (United States) founded in 2003. It operates as a therapeutics for the regulation of hematopoietic ststem. Cellerant has raised $51.04 million across 19 funding rounds from investors including HHS, Allen & Company and SBIR. The company has 1 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is CELLERANT THERAPEUTICS, INC. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Cellerant Therapeutics is a biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. The company is developing a novel, cell-based medicine (Myeloid Progenitors CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. In addition, Cellerant is also exploring candidates targeting cancer stem cells.
- Headquarters San Carlos, United States
- Employees 1
- SectorsHealthcare
- Website cellerant.com
- Social LinkedIn
- Legal Name Cellerant Therapeutics, Inc.
- Total Equity Funding$51.04M (USD)
in 19 rounds
- Latest Funding Round$6.55M (USD), Debt – Conventional
Feb 2019
- InvestorsHHS
& 7 more
- Employee Count1
Funding Insights of Cellerant
Cellerant has successfully raised a total of $51.04M across 19 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $6.55 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.04M
- Total Rounds 19
- Last Round Debt – Conventional — $6.55M
- First Round $10M
(May 2003)
- Investors Count 8
Latest 10 of 19 funding rounds of Cellerant with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $6.55M | Debt – Conventional | – | – | – |
| Sep 2016 | $1.5M | Grant | – | – | |
| Apr 2016 | $2.03M | Debt – Conventional | – | – | – |
| Jan 2014 | $2.19M | Series C | – | – | – |
| Aug 2013 | $1.04M | Grant | – | – | |
| Sep 2012 | $2.09M | Series C | – | – | – |
| Aug 2011 | $800,000 | Series C | – | – | – |
| Apr 2011 | $2.02M | Series C | – | – | – |
| Jun 2010 | $4.54M | Series C | – | – | – |
| Sep 2009 | $1M | Grant | – | – |
8 investors in total: 8 institutional.
Investors in Cellerant
Cellerant has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Allen & Company and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | camelotvg.com | - | |
- | – | eminentcp.com | - | |
Early-stage tech startups are funded by Black Diamond Ventures. | – | bdventures.com | Los Gatos, United States | |
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Wealth management firm | 1932 | alleninvestments.com | Lakeland, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | – | mpmcapital.com | - | |
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States |
Investor details for Cellerant
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cellerant
3 dated milestones of Cellerant across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Cellerant is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Debt – Conventional, of $6.5M.
Competitors of Cellerant
Cellerant has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Cellerant
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellerant
Websites that share an audience with Cellerant (cellerant.com).
Websites whose visitors overlap most with Cellerant. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| viacellinc.com | 100% | – | – | View details | |
| intercytex.com | 100% | – | – | View details | |
| pluristem.com | 78% | – | – | View details |
Top companies in Cell Therapy
10 companies that operate in the same segment as Cellerant (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellerant
Complete news archive for Cellerant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellerant
Cellerant was founded in 2003.
Cellerant is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Cellerant is a funded company, having raised a total of $51.04M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on May 2003.
Cellerant has 1 employees.
Cellerant Therapeutics is a biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. The company is developing a novel, cell-based medicine (Myeloid Progenitors CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. In addition, Cellerant is also exploring candidates targeting cancer stem cells.
Cellerant's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Cellerant has 8 investors. Key investors include HHS, Allen & Company, SBIR, Turmeric Acquisition Corp, and Camelot Venture Group.
Cellerant operates through Cellerant Therapeutics, Inc..